We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
MSD has announced the European approval of two of its products for the treatment of HIV: the single-tablet combination Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate)